|
|
||||||||
Part 4: Inflammation and Fibrosis |
1 Department of Internal Medicine, Yeungnam University Hospital, 2 and Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea
Correspondence to: Jun-Young Do, Department of Internal Medicine, Yeungnam
University College of Medicine, Daegu 705-717
Korea.
jydo{at}med.yu.ac.kr
We examined peritoneal growth factors, mesothelial mass, and
epithelial-to-mesenchymal transition (EMT) in response to peritoneal exposure
to peritoneal dialysate with standard and low concentrations of glucose
degradation products (GDPs). We randomized 56 incident continuous ambulatory
peritoneal dialysis (CAPD) patients to receive either low-GDP (30 patients) or
high-GDP (standard) peritoneal dialysis (PD) solution (26 patients). The
effects of the PD solutions on EMT and peritoneal growth factors in overnight
dialysate effluent were compared at 1, 6, and 12 months. Assessment of EMT was
performed after human peritoneal mesothelial cells (HPMCs) were cultured from
overnight effluent. The low-GDP solution group showed significantly higher
dialysate levels of cancer antigen 125 (CA125), fibronectin, transforming
growth factor β(TGFβ)-induced gene product (βig-h3), and
interleukin-6 (IL-6), but the rate of EMT was significantly lower in the
low-GDP solution group during the initial 12 months of CAPD treatment. After
adjusting peritoneal growth factors for dialysate CA125 concentration, the
low-GDP solution group showed significantly lower ratios of fibronectin/CA125,
βig-h3/CA125, IL-6/CA125, TGFβ/CA125, and vascular endothelial
growth factor (VEGF)/CA125 than did patients in the high-GDP (standard)
solution group. Factors associated with higher EMT were the type of solution
(high in GDPs), the mass of HPMCs (low CA125), and higher VEGF/CA125.
Adjustment of dialysate VEGF for effluent CA125 revealed a significant
association with EMT. It suggests that fibroblastoid transition from HPMCs
could be affected by the intraperitoneal VEGF per unit mass of HPMCs.
KEY WORDS: cancer antigen 125; CA125; epithelial-to-mesenchymal transition; EMT; glucose degradation products; GDPs; peritoneal growth factors.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |